- Overview of Key Characteristics and Practical Considerations for Novel ART Paradigms
- Panel Discussion: Key Questions on Oral 2-drug ART Regimens
- Panel Discussion: Key Questions on Injectable Long-acting ART
- Questions and Answers
Date / Time
Ciudad de México, CDMX,
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Andrea Mantsios, PhD
Center for Health, Risk and Society
Anthony M. Mills, MD
President, Southern California Men's Medical Group
CEO and CMO, Men's Health Foundation
President & Clinical Research Director, Mills Clinical Research
Assistant Professor of Clinical Medicine
University of California, Los Angeles
Los Angeles, California
Omar Sued, MD, PhD
Director, Research Department
Buenos Aires, Argentina
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
The goal of this activity is to improve participants’ knowledge and competence regarding the clinical role of innovative antiretroviral regimens.
This program is intended for physicians and other healthcare professionals who provide care for HIV-infected patients.
- Incorporate innovate ART strategies into the management of persons with HIV infection based on key data and practice guidelines
- Appraise 2-drug vs 3-drug treatment strategies in the care of persons with HIV infection
- Devise strategies to incorporate the use of long-acting ART as a treatment option for appropriate candidates, once available
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.